WallStreetZenWallStreetZen

NYSE: PEN
Penumbra Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PEN

Based on 12 analysts offering 12 month price targets for Penumbra Inc

Min Forecast
$266.00-11.53%
Avg Forecast
$306.00+1.78%
Max Forecast
$355.00+18.07%

Should I buy or sell PEN stock?

Based on 12 analysts offering ratings for Penumbra Inc.

Strong Buy
Strong Buy
6 analysts 50%
Buy
3 analysts 25%
Hold
3 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PEN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PEN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PEN stock forecasts and price targets.

PEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-06Find Out Why
lockedlocked$00.00+00.00%2025-10-27
lockedlocked$00.00+00.00%2025-10-27
lockedlocked$00.00+00.00%2025-10-15
Evercore ISI Group
Bottom 16%
16
BuyMaintains$285.00-5.21%2025-10-07
Morgan Stanley
Bottom 13%
13
HoldMaintains$266.00-11.53%2025-07-31
Truist Securities
Top 16%
85
Strong BuyMaintains$310.00+3.11%2025-07-30Find out why
UBS
Top 45%
56
Strong BuyMaintains$335.00+11.42%2025-07-30Find out why
RBC Capital
Top 20%
81
BuyMaintains$325.00+8.10%2025-07-30

1 of 2

Forecast return on equity

Is PEN forecast to generate an efficient return?

Company
22.37%
Industry
28.51%
Market
228.52%
PEN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PEN forecast to generate an efficient return on assets?

Company
17.43%
Industry
13.33%
PEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PEN earnings per share forecast

What is PEN's earnings per share in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$3.80-10.13%
Avg 2 year Forecast
$5.10+20.56%
Avg 3 year Forecast
$6.47+52.92%
PEN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

PEN revenue forecast

What is PEN's revenue in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$1.4B+4.59%
Avg 2 year Forecast
$1.6B+19.36%
Avg 3 year Forecast
$1.8B+35.4%
PEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PEN earnings growth forecast

How is PEN forecast to perform vs Medical Devices companies and vs the US market?

Company
15.13%
Industry
14.32%
Market
42.88%
PEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
PEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
PEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

PEN revenue growth forecast

How is PEN forecast to perform vs Medical Devices companies and vs the US market?

Company
10.57%
Industry
7.13%
Market
25.67%
PEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PEN vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
PEN$300.66$306.00+1.78%Strong Buy
GMED$91.10$91.88+0.85%Strong Buy
ALGN$157.21$171.25+8.93%Buy
SNN$33.48$34.00+1.55%Hold
BIO$317.69$374.67+17.93%Buy
View Top Medical Device Stocks

Penumbra Stock Forecast FAQ

Is Penumbra Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NYSE: PEN) stock is to Strong Buy PEN stock.

Out of 12 analysts, 6 (50%) are recommending PEN as a Strong Buy, 3 (25%) are recommending PEN as a Buy, 3 (25%) are recommending PEN as a Hold, 0 (0%) are recommending PEN as a Sell, and 0 (0%) are recommending PEN as a Strong Sell.

If you're new to stock investing, here's how to buy Penumbra stock.

What is PEN's earnings growth forecast for 2025-2027?

(NYSE: PEN) Penumbra's forecast annual earnings growth rate of 15.13% is forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 14.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Penumbra's earnings in 2025 is $164,027,000.On average, 22 Wall Street analysts forecast PEN's earnings for 2025 to be $148,882,848, with the lowest PEN earnings forecast at $140,083,107, and the highest PEN earnings forecast at $160,369,115. On average, 22 Wall Street analysts forecast PEN's earnings for 2026 to be $199,719,270, with the lowest PEN earnings forecast at $181,532,355, and the highest PEN earnings forecast at $223,283,152.

In 2027, PEN is forecast to generate $253,324,458 in earnings, with the lowest earnings forecast at $227,587,075 and the highest earnings forecast at $290,309,218.

What is PEN's revenue growth forecast for 2025-2027?

(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 10.57% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Penumbra's revenue in 2025 is $1,333,798,000.On average, 22 Wall Street analysts forecast PEN's revenue for 2025 to be $54,631,236,915, with the lowest PEN revenue forecast at $52,868,938,950, and the highest PEN revenue forecast at $57,020,129,712. On average, 22 Wall Street analysts forecast PEN's revenue for 2026 to be $62,346,185,784, with the lowest PEN revenue forecast at $59,487,346,863, and the highest PEN revenue forecast at $65,714,133,006.

In 2027, PEN is forecast to generate $70,726,891,662 in revenue, with the lowest revenue forecast at $66,654,025,254 and the highest revenue forecast at $75,113,055,486.

What is PEN's forecast return on assets (ROA) for 2025-2028?

(NYSE: PEN) forecast ROA is 17.43%, which is higher than the forecast US Medical Devices industry average of 13.33%.

What is PEN's Price Target?

According to 12 Wall Street analysts that have issued a 1 year PEN price target, the average PEN price target is $306.00, with the highest PEN stock price forecast at $355.00 and the lowest PEN stock price forecast at $266.00.

On average, Wall Street analysts predict that Penumbra's share price could reach $306.00 by Nov 6, 2026. The average Penumbra stock price prediction forecasts a potential upside of 1.78% from the current PEN share price of $300.66.

What is PEN's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: PEN) Penumbra's current Earnings Per Share (EPS) is $4.23. On average, analysts forecast that PEN's EPS will be $3.80 for 2025, with the lowest EPS forecast at $3.58, and the highest EPS forecast at $4.10. On average, analysts forecast that PEN's EPS will be $5.10 for 2026, with the lowest EPS forecast at $4.64, and the highest EPS forecast at $5.70. In 2027, PEN's EPS is forecast to hit $6.47 (min: $5.81, max: $7.41).

What is PEN's forecast return on equity (ROE) for 2025-2028?

(NYSE: PEN) forecast ROE is 22.37%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.